文献速递肿瘤 PET/CT神经核医学

SDHB相关转移性副神经节瘤中68Ga-DOTATATE与68Ga-DOTANOC的相关不一致性:对生长抑素受体2的亲和力是关键吗?

Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key?
PubMed 文献 · Clin Nucl Med · 2017-01-01

本文报告一例SDHB相关转移性副神经节瘤患者,在7个月内先后接受68Ga-DOTANOC和68Ga-DOTATATE PET/CT检查,68Ga-DOTANOC PET/CT扫描几乎阴性,而68Ga-DOTATATE PET/CT识别出多个高阳性病灶,提示目前使用的Ga-DOTA肽对生长抑素受体亲和力不同。

要点

  • 嗜铬细胞瘤/副神经节瘤过表达生长抑素受体2。
  • 同一患者68Ga-DOTANOC PET/CT几乎阴性,68Ga-DOTATATE PET/CT见多个高阳性病灶。
  • 不同Ga-DOTA肽对生长抑素受体亲和力不同,可能导致显像结果不一致。

核心结论

  • 在SDHB相关转移性副神经节瘤患者中,68Ga-DOTANOC与68Ga-DOTATATE PET/CT可呈现显著差异,68Ga-DOTANOC扫描几乎阴性而68Ga-DOTATATE识别多个高阳性病灶。
  • 作者提出对生长抑素受体2的亲和力可能是这种不一致性的关键。

研究设计与样本

  • 病例报告:一例SDHB相关转移性副神经节瘤患者在7个月内先后接受68Ga-DOTANOC和68Ga-DOTATATE PET/CT检查。

主要发现

  • 68Ga-DOTANOC PET/CT扫描几乎阴性。
  • 68Ga-DOTATATE PET/CT识别出多个高阳性病灶。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Pheochromocytomas/paragangliomas are somatostatin receptor 2-overexpressing tumors. Ga-DOTA-peptide imaging has recently shown excellent results in the detection of metastatic lesions in these tumors. However, currently used Ga-DOTA peptides show different somatostatin receptor affinities. Here, we report the remarkable differences in a patient who was imaged with Ga-DOTANOC and Ga-DOTATATE PET/CT within a 7-month period. The patient presented with a nearly negative Ga-DOTANOC PET/CT scan, whereas on Ga-DOTATATE PET/CT, multiple highly positive lesions were identified.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Janssen I, Wolf KI, Chui CH, et al. Relevant Discordance Between 68Ga-DOTATATE and 68Ga-DOTANOC in SDHB-Related Metastatic Paraganglioma: Is Affinity to Somatostatin Receptor 2 the Key? Clin Nucl Med. 2017. PMID: 28033222. doi:10.1097/RLU.0000000000001504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。